Related by context. All words. (Click for frequent words.) 87 Pivotal Phase 86 Initiates Phase 85 Randomized Phase 84 Meets Primary Endpoint 84 Successfully Completes Phase 84 Initiates Phase II 83 Initiates Phase III 83 Commences Phase 83 Phase 2b Clinical Trial 83 Completes Patient Enrollment 82 Commence Phase 82 Pivotal Phase III 82 Initiated Phase 80 Trial Evaluating 80 Second Pivotal Phase 80 Phase IIb Trial 80 Completes Enrollment 80 Initiates Clinical 80 Phase 2b Trial 80 Study Evaluating 79 Drug Candidate 79 Presents Positive 79 Oral Fingolimod 79 Receives Orphan Drug Designation 79 Clinical Trial Results 79 Initiates Enrollment 79 Confirmatory Phase 79 Initiates Clinical Trial 78 Initiates Phase 2b 78 Phase III Clinical Trial 78 Phase IIb Clinical Trial 78 Files IND 78 Metastatic Melanoma 78 Combination REOLYSIN R 78 Novel Oral 77 Phase 2a Trial 77 Prolongs Survival 77 Begins Dosing 77 Phase III Pivotal 77 Dose Ranging Study 77 Phase III Trial 77 Initiate Phase III 77 II Clinical Trial 77 Patient Enrollment 77 Protease Inhibitor 77 Presents Preclinical Data 77 Randomized Phase II 77 Phase 2a Clinical Trial 77 Oral Calcitonin 77 IND Application 77 Phase 2b Study 77 Adjuvant Treatment 77 Aflibercept 77 Presents Preclinical 76 Pivotal Trial 76 Multiple Ascending Dose 76 Pooled Analysis 76 Phase 1b Clinical Trial 76 FDA Accepts 76 Preclinical Data 76 Demonstrates Potent 76 initiated Phase Ib 76 Randomized Double Blind 76 Investigational Oral 76 PRN FDA Approves 76 Phase IIa Clinical Trial 76 Submits NDA 76 First Patient Dosed 76 Hsp# Inhibitor 76 Clinical Trial Evaluating 76 Pivotal Study 76 Severe Sepsis 76 Demonstrates Significant 75 Submits IND 75 Kinase Inhibitor 75 dependent kinase inhibitor 75 Achieves Primary Endpoint 75 Testosterone MDTS ® 75 Hormone Refractory Prostate Cancer 75 JAK Inhibitor 75 Granted Orphan Drug 75 Antitumor Activity 75 Pivotal Phase II 75 Randomized Double blind 75 Investigational Compound 75 Cutaneous T 75 Vascular Disrupting Agent 75 Complicated Skin 75 PHASE III 75 JAK2 Inhibitor 74 TO AVOID PREGNANCY WHILE 74 First Patient Enrolled 74 non nucleoside inhibitor 74 Sapacitabine 74 Demonstrates Positive 74 Tezampanel 74 Files Investigational 74 Initiate Clinical Trial 74 Patients Treated With 74 Fast Track Status 74 oral prodrug 74 PEGylated Fab fragment 74 Present Preclinical Data 74 Investigational Drug 74 Single Dose 74 Tyrosine Kinase Inhibitor 74 Drug Fails 74 Pulmonary Arterial Hypertension 74 Phase III Trials 74 Dose Escalation 74 treatment naive genotype 74 FOLOTYN ® 74 NDA Submission 74 Advanced Melanoma 74 Diabetic Nephropathy 74 Previously Treated 73 Safinamide 73 Lupus Drug 73 Double Blind Placebo 73 Bosutinib 73 Chronic Hepatitis C 73 Vicriviroc 73 Parathyroid Hormone 73 adecatumumab MT# 73 Topline Results 73 Romidepsin 73 Recombinant Human 73 selective phosphodiesterase 73 humanized interleukin 6 73 MKC# MT 73 HDAC Inhibitor 73 Prospective Randomized 73 Prostate Cancer Vaccine 73 IND Filing 73 novel VDA molecule 73 Brentuximab Vedotin SGN 73 Collaborators Present 73 Randomized Double Blind Placebo 73 dasatinib Sprycel ® 73 selective A2A adenosine receptor 73 Maribavir 73 SPRYCEL ® 73 Telaprevir VX 73 Systemic Delivery 73 Disease Modifying 73 pralatrexate injection folate analogue 73 Receives Milestone Payment 73 Newly Diagnosed Multiple Myeloma 73 Refractory Hodgkin Lymphoma 73 LUX Lung 73 Pharmacokinetic Study 73 Phase Ib Clinical Trial 73 Initiates Clinical Trials 73 R roscovitine CDK cyclin 73 Anti Tumor 73 Investigational Treatment 73 Mg Usa 73 Receptor Agonist 73 Patient Enrolment 73 Mylan Receives Approval 73 multicenter Phase 73 Study Showed 73 Receives Fast Track 73 ALN HPN 72 Controlled Trial 72 Receives Orphan Drug 72 registrational Phase 72 Ozarelix 72 FDA Approvals 72 Preclinical Study 72 Transdermal Patch 72 Treatment Naïve 72 Testosterone MDTS R 72 Multicenter Phase 72 TKB# 72 Novel Antibiotic 72 Preclinical Models 72 Submits Biologics License Application 72 virus HCV protease inhibitor 72 Potent Antiviral Activity 72 Demonstrated Significant 72 Anticancer Compound 72 Improves Survival 72 Adjunctive Therapy 72 Therapeutic Competitors Companies 72 RNAi Therapeutic 72 randomized controlled Phase 72 Receptor Antagonist 72 Initiates Dosing 72 Relapsing Multiple Sclerosis 72 Phase 2a Study 72 Completes Dosing 72 LymphoStat B belimumab 72 Receives Approvable Letter 72 placebo controlled Phase 72 HCV SPRINT 72 PEG IFN 72 Phase #b/#a clinical 72 Angiotensin Converting Enzyme 72 generation purine nucleoside 72 Omacetaxine 72 Lung Cancer Drug 72 Combination Treatment 72 TELINTRA R 72 Lenocta TM 72 AAG geldanamycin analog 72 BRIM2 72 telomerase therapeutic 72 Peginterferon 72 Peginterferon Alfa 2a 72 albiglutide 72 ABLYNX 72 pan histone deacetylase 72 Taro Receives 72 Oral Cladribine 72 Initiate Phase II 72 By JENNIFER LEARN 72 Well Tolerated 72 Reports Preclinical Data 72 Improves Outcomes 72 Receive Milestone Payment 72 Phase III Clinical Trials 72 Monoclonal Antibody 72 Randomized Phase III 72 sodium glucose cotransporter 72 IIa Clinical Trial 72 Personalized Immunotherapy 72 Dose Finding 72 Cloretazine ® 72 R lenalidomide 72 Polymerase Inhibitor 72 Lupus Nephritis 72 Earns Milestone Payment 72 FDA APPROVES 72 TLK# 72 Matrix Phase 2b 71 Presents Positive Preclinical 71 Orally Active 71 CCX# B 71 including eniluracil ADH 71 Vaccine Adjuvant 71 Pharmacokinetics PK 71 Elagolix 71 Novel Inhibitor 71 Xeloda ® 71 Intravitreal 71 FDA Clears 71 Dose Ranging 71 Phase Ib II 71 Is Well Tolerated 71 Shows Promising 71 comparing alemtuzumab 71 Synta Announces 71 dose escalation clinical 71 Efficacy Results 71 Ecallantide 71 BioSante Pharmaceuticals Announces 71 AN# topical anti 71 diarrhea predominant irritable 71 Long Term Efficacy 71 Luramist TM 71 Phase IIIb clinical 71 Pivotal Trials 71 VEGFR2 inhibitor 71 LymphoStat B TM 71 Trandolapril 71 Glufosfamide 71 Desvenlafaxine Succinate 71 Perifosine KRX 71 Lung Cancer Trial 71 Submits Response 71 AZX# Phase 71 agonistic human 71 Early Relapsing Multiple 71 Million Milestone Payment 71 Demonstrates Potential 71 treatment naïve genotype 71 Teva Provides Update 71 Announces Initiation 71 oral nucleoside analogue 71 interferon gamma 1b 71 Drug Shows Promise 71 phase Ib 71 Announces Tentative Approval 71 Hydrochlorothiazide Tablets 71 Pafuramidine 71 Phase Ib clinical 71 PDUFA Date 71 Spectrum Pharmaceuticals Announces 71 methylnaltrexone bromide 71 Relapsed Refractory 71 drug pipeline TAFA# 71 Metastatic Colorectal Cancer 71 evaluating tivozanib 71 mGluR5 negative 71 Pivotal Clinical Trial 71 Efficacy Trial 71 diarrhea fatigue asthenia 71 orally administered inhibitor 71 Mg Uk 71 Glatiramer Acetate 71 multicenter Phase III 71 Diabetic Neuropathy 71 REG1 Anticoagulation System 71 Plus Ribavirin 71 refractory chronic lymphocytic 71 HCV RNA polymerase 71 Fungal Infections 71 Rigel R# 71 Aurora Kinase 71 Patients Enrolled 70 Rheumatoid Arthritis Drug 70 Phase Ib IIa 70 Novel Compound 70 Antiviral Activity 70 Pralatrexate 70 Statistically Significant 70 IN PATIENTS WITH 70 ACTEMRA TM 70 cetuximab Erbitux R 70 Migraine Drug 70 Immunotherapeutic 70 Randomised 70 APEX PD 70 PNP inhibitor 70 Tesamorelin 70 Crofelemer budesonide foam 70 Therapeutic Vaccine 70 MAGE A3 ASCI 70 ongoing Phase 1b 70 PEGylated anti 70 evaluating mipomersen 70 Patients Treated 70 topical gel formulation 70 Benign Prostatic Hyperplasia 70 induced macular edema 70 Milestone Payment 70 Sagent Pharmaceuticals Announces 70 approved incretin mimetic 70 fidaxomicin Phase 70 Immunomedics Announces 70 2 methoxyestradiol 70 Myeloma Patients 70 phase IIa 70 Shows Efficacy 70 Relapsed Multiple Myeloma 70 CCR5 mAb 70 Placebo Controlled 70 Controlled Study 70 Completes Patient Enrolment 70 FEMALES SHOULD BE ADVISED 70 beta 1a 70 lintuzumab SGN 70 Archexin 70 inflammatory PDE 70 Systemic Sclerosis 70 XL# anticancer compounds 70 Infected Patients 70 Multicenter Randomized 70 INSPIRE Trial Phase III 70 receptor tyrosine kinase inhibitor 70 evaluating picoplatin 70 alfa 2a 70 Announce Initiation 70 Anticancer Agent 70 Anti Tumor Activity 70 Epratuzumab 70 markets Testim ® 70 Late Breaker 70 Phase IIA 70 Romiplostim 70 Treat Anemia 70 Plaque Psoriasis 70 Abiraterone Acetate 70 Drug Eluting Stent System 70 Anticancer Drug 70 Soft Tissue Sarcoma 70 cutaneous T 70 phase IIb clinical 70 Novel Mechanism 70 Insulin Glargine 70 Hematological Malignancies 70 Treated Patients 70 Enrolls First 70 CYP#A# CYP#D# 70 Postmenopausal Osteoporosis 70 Histone Deacetylase 70 Tipranavir 70 Phase Ib clinical trials 70 Ceflatonin R 70 Treatment Naive Patients 70 Cyclooxygenase Inhibiting Nitric Oxide 70 lexidronam injection 70 Luveniq 70 vapreotide acetate 70 novel histone deacetylase 70 Renal Cell Carcinoma 70 GOUT 70 Gout Drug 70 novel orally inhaled 70 antibody MAb 70 polymerase inhibitor 70 Naive Patients 70 phase IIb 70 blinded randomized placebo controlled 70 EVIZON TM 70 PRE SURGE 70 Announces Poster Presentations 70 Investigational Agent 70 Shows Statistically Significant 70 R#/MEM # 70 Melphalan 70 Aliskiren 70 Daclizumab 70 Darinaparsin 70 Clinical Study Shows 69 Randomized Clinical Trial 69 Placebo Controlled Trial 69 GW# [003] 69 phase III isavuconazole 69 Rotavirus Vaccine 69 CYT# potent vascular disrupting 69 ORENCIA ® 69 Arthritis Drug 69 Monotherapy 69 assessing T DM1 69 Antiangiogenic 69 Panzem R 69 MKC# 69 IL# PE#QQR 69 Phase III Pivotal Trial 69 Telik logo TELINTRA 69 Osteoporosis Drug 69 Forodesine HCl 69 Medoxomil 69 Receptor Antagonists 69 Bayer HealthCare Onyx Pharmaceuticals 69 multicenter phase 69 BRIM3 69 5 fluorouracil leucovorin 69 Anticancer Activity 69 Therapeutic Competitors companiesandmarkets.com adEgemonye 69 Interferon Beta 69 essential thrombocythemia ET 69 Patients Receiving 69 Humanized Anti 69 Subgroup Analysis 69 Peginterferon alfa 2b 69 Denufosol 69 Remission Maintenance 69 developing Bicifadine serotonin 69 vesicular monoamine transporter 69 Develop Novel 69 Silodosin 69 Azacitidine 69 Pegloticase 69 alvespimycin 69 Cell Lymphoma 69 Janus kinase 69 Calcium Acetate 69 HCV Protease Inhibitor 69 Expanded Indication 69 Phase 1a clinical 69 Vitro Activity 69 KSP inhibitor 69 Xcytrin R 69 TNF Tumor Necrosis Factor 69 FDA Okays 69 pharmacogenomic translational research 69 Oral Insulin 69 midstage clinical 69 Vildagliptin 69 Oral Insulin Capsule 69 histone deacetylase HDAC inhibitor 69 Nicotine Vaccine 69 JZP 69 plus Copegus R 69 Sangamo BioSciences Announces 69 AKT inhibitor 69 Epilepsy Drug 69 Ranolazine 69 PF # [002] 69 fosbretabulin 69 Tocilizumab 69 lead Aganocide compound 69 retinal vein occlusion induced 69 Double Blind Randomized 69 allosteric modulator NAM 69 Oral Formulation 69 evaluating satraplatin 69 Milestone Payments 69 Shows Promise Against 69 TMC# C# 69 Agonist MABA program 69 Safety Tolerability 69 include Phenoptin TM 69 Acute Attacks 69 Myelofibrosis 69 Pegylated Liposomal Doxorubicin 69 PANVAC VF 69 Inhalation Aerosol 69 Reveals Positive 69 Multicenter 69 HGS ETR2 69 Prednisone Against Refractory 69 orally inhaled migraine 69 Attenuates 69 Commences Phase III 69 Dendritic Cells 69 Begin Clinical Trials 69 forodesine 69 metastatic castrate resistant 69 toenail onychomycosis 69 Metformin HCl 69 product candidate Lpathomab 69 Intravenous Formulation 69 anti botulism antibody 69 AEGR 69 controlled multicenter Phase 69 Recurrent Glioblastoma 69 brivanib 69 Phase IIIb 69 Acute Ischemic Stroke 69 gastrin analogue TT 69 HCV Genotype 69 Parkinson disease levodopa induced 69 Clinical Evaluation 69 Milestone Payment From 69 Iloperidone 69 AVAPRO 69 Demonstrates Efficacy 69 Capsules CII 69 Hepatitis B Vaccine 69 2 inhibitor CYT# 69 immunosuppressive compound 69 Forodesine 69 MKC# MKC# PP 69 RECORD1 69 liposomal formulation 69 MEND CABG II 69 Sandostatin R 69 Dasatinib 69 BENLYSTA ® 69 Improved Survival 69 Submits Investigational 69 mertansine 69 Demonstrate Significant 68 Phase III multicenter 68 APPRAISE 68 THERAPEUTICS 68 vinorelbine tartrate 68 FOLFOX6 chemotherapy regimen 68 Mycophenolate Mofetil 68 Treatment Experienced 68 Orally administered 68 Significantly Improves 68 Granulocyte Colony Stimulating Factor 68 Low Dose 68 Hypertensive Patients 68 Antibody Drug Conjugate 68 GALNS 68 Vitrasert R 68 Custirsen 68 pan HDAC inhibitor 68 generation Hsp# inhibitor 68 Inhaled Insulin 68 Receives Positive Opinion 68 MEK Inhibitor 68 Chronic Lymphocytic Leukemia 68 SinuNase TM 68 selective androgen receptor modulator 68 Nitazoxanide 68 Contrave# 68 Randomized Controlled 68 myelodysplastic myeloproliferative diseases 68 Medullary Thyroid Cancer 68 Metabolic Efficiency 68 HuMax EGFr 68 Xyfid TM 68 VentiRx Pharmaceuticals 68 antibody blinatumomab MT#/MEDI-# 68 erlotinib Tarceva ® 68 Antigen Specific 68 Plicera 68 Intervention Effectiveness 68 Toremifene 68 Advanced Renal Cell 68 Cites Positive 68 Generic Version 68 ritonavir boosted 68 Maleate 68 Previously Untreated 68 Irinotecan 68 signal detection CTSD 68 TransVax 68 Receives Complete Response 68 selective modulator 68 includes TOLAMBA TM 68 investigational humanized monoclonal antibody 68 compound INCB# 68 Enzyme Replacement Therapy 68 mGluR2 positive 68 Potent Inhibitor 68 Seliciclib CYC# 68 Novel Anti Inflammatory 68 Randomized Study 68 Epothilone D 68 omacetaxine mepesuccinate 68 PROVENGE ® 68 Survival Benefit 68 Tesetaxel 68 Cholesterol Lowering Drug 68 systemic Phase 1b 68 elotuzumab 68 occlusion PAO 68 Prostate AdenoCarcinoma Treatment 68 Schizophrenia Drug 68 Syncria R 68 Nasdaq XTLB 68 8mg/kg 68 Abstract Accepted 68 huC# DM4 68 Ofatumumab 68 docetaxel Taxotere R 68 phase IIa clinical 68 Degarelix 68 cromolyn sodium 68 investigational protease inhibitor 68 phase Ib clinical 68 Myelodysplastic Syndrome MDS 68 systemic juvenile idiopathic 68 relapsed MM 68 GVAX ® 68 Novel Therapeutic 68 RNAi Therapeutics 68 Annamycin 68 Chronic Hepatitis B 68 Dose Escalation Study 68 Inhalation Solution 68 ALN PCS 68 Psoriasis Drug 68 Hydrochloride Tablets 68 Albuferon TM 68 ® lenalidomide 68 TRANSFORMS 68 Sirolimus Eluting Stent 68 Nasdaq VNDA 68 Ambrisentan 68 Bortezomib 68 LAB CGRP 68 phase IIb study 68 Adjuvant Therapy 68 baminercept 68 Blood Pressure Drug 68 sodium thiosulfate STS 68 generation antisense inhibitor 68 TRO# 68 Febuxostat 68 Metastatic Renal Cell Carcinoma 68 Resistant Hypertension 68 Anti CD# Antibody 68 Panzem R NCD 68 sunitinib Sutent ® 68 Suppl. 68 Diabetic Foot Ulcer 68 evaluating satraplatin plus 68 familial amyloidotic polyneuropathy FAP 68 J Am Coll 68 Factor Receptor 68 J Clin 68 Cannabinor 68 influenza BCX# purine nucleoside 68 NSABP B 68 Malignant Melanoma 68 J Allergy Clin 68 Biogen Genentech 68 receptor modulators 68 Blind Placebo Controlled Trial 68 sarcoma melanoma 68 severe oral mucositis 68 dasatinib Sprycel 68 Ovitrelle R Serostim 68 Phase IIb trials 68 ADP receptor antagonist 68 Golimumab 68 Telithromycin 68 stated Michelle Berrey 68 Licenses Novel 68 azilsartan medoxomil 68 Ondansetron Injection USP 68 MBRX 68 Receives FDA Clearance 68 Varespladib 68 Submits Supplemental 68 Liposomal 68 IIa clinical 68 TRACON Pharmaceuticals Inc. 68 balsalazide disodium Capsules 68 Risperidone Oral Solution 68 Seasonal Influenza Vaccine 68 Hepatitis C Genotype 68 STEALTH C 68 Vaccine Candidate 68 REG2 68 trastuzumab Herceptin R 68 Supplemental Biologics License Application 68 NDTV HINDU # 68 HCV RESPOND 2 68 Crit Rev 68 hyaluronidase enzyme 68 PEG SN# 68 KRN# 68 antibody MT# 68 prucalopride 68 dyskinesia PD LID 68 Phase 1b clinical trials 68 oral ridaforolimus 68 Pimavanserin 68 Gets FDA Clearance 68 evaluating bafetinib 68 Emtriva Viread 68 class anticancer quinolone 68 Pancreas Cancer Vaccine 68 Clinical Trials Update 68 Neulasta R 68 BENLYSTA ™ 68 Slow Progression 68 Ocrelizumab 68 Nasdaq EPCT 68 Vascular Inflammation 68 See CLINICAL PHARMACOLOGY 68 Integrase Inhibitor 68 Prospective Multicenter 68 Demonstrates Sustained 68 RANK Ligand inhibitor 68 Neoadjuvant 68 docetaxel Taxotere ® 68 phase IIb III 68 5q MDS 67 Am J Obstet 67 ThermoDox R 67 E1 INT TM 67 SAR# [002] 67 combines bupropion 67 Placebo Controlled Study 67 dextromethorphan quinidine 67 protein tyrosine phosphatase 1B 67 Decitabine 67 CALGB # [002] 67 MT# MEDI 67 Gastrointestinal Stromal Tumors 67 Preclinical Efficacy 67 Nuvelo Announces 67 GetGoal Phase III 67 Adjuvant Chemotherapy 67 Treatment Resistant 67 CTAP# Injection 67 PKC# 67 multicenter Phase II 67 ISTODAX ® 67 Generic Versions 67 Methylnaltrexone 67 Advanced Colorectal Cancer 67 Stent Restenosis 67 Novel Small Molecule 67 2A receptor agonist 67 Diffuse Large B 67 PROCTOCORT R 67 FDA Approvable Letter 67 Phase IIB 67 Fixed Dose 67 Cancer Cachexia 67 ZYBRESTAT TM 67 ARRY # 67 Successfully Treated 67 Zorbtive TM 67 EOquin TM phase 67 AEG# 67 Civacir 67 Tiotropium 67 Mouse Model 67 Levoleucovorin 67 trastuzumab DM1 T DM1 67 Clostridium difficile Infection 67 fostamatinib 67 Saxagliptin 67 Collaborators Publish 67 Clevudine 67 benzoic acid hyoscyamine sulfate 67 acute peripheral arterial 67 hypoxia activated prodrug 67 Versus Placebo 67 GTC recombinant form 67 Cethromycin 67 Transdermal System 67 registrational trial 67 Announce License Agreement 67 Randomized Clinical Trials 67 AVONEX ® 67 Advaxis Phase 67 Kahalalide F 67 EARNINGS LOOK AHEAD 67 Diamyd Medical Diamyd 67 Tanespimycin 67 Neovascular Age Related Macular 67 soluble tumor necrosis 67 IMPACT DCM 67 Copegus ribavirin 67 Antiplatelet 67 CD# CEA 67 #mg/#mg 67 Cetrorelix 67 evaluating T DM1 67 acyclovir Lauriad R 67 Nebulized 67 Pegylated 67 Anturol TM 67 initiate Phase IIa 67 sapropterin dihydrochloride Phase 67 Relapsing Remitting Multiple Sclerosis 67 Lubiprostone 67 Amigal TM 67 Node Positive 67 Demonstrates Statistically Significant 67 Improve Survival 67 Voreloxin 67 Therapeutic Antibody 67 MEK inhibitor 67 GATTEX TM 67 novel nucleoside analog 67 refractory gout 67 Vitaxin 67 PRTX 67 Inhibits 67 HCl Tablets 67 CLINICAL TRIAL 67 Metastatic Prostate Cancer 67 miconazole Lauriad R 67 Fondaparinux 67 Hemodialysis Patients 67 Bazedoxifene 67 LibiGel ® 67 Linagliptin 67 metaglidasen 67 Ziprasidone 67 SinuNase ™ 67 initiated confirmatory Phase 67 Capecitabine 67 IMPACT IMmunotherapy 67 systemic anaplastic large 67 ® decitabine 67 Monopril 67 IMiDs ® 67 Adenoviral 67 nucleotide analog 67 markets COLAZAL 67 Pegylated Interferon 67 Sprycel dasatinib 67 Castration Resistant Prostate Cancer 67 cancer neuroendocrine tumor 67 Left Ventricular Dysfunction 67 #nd EORTC NCI 67 Clinical Efficacy 67 Cholesterol Drug 67 ACCLAIM COPD 67 Antiviral Therapy 67 generation PNP inhibitor 67 Epidermal Growth Factor Receptor 67 Synthetic Peptide 67 miconazole Lauriad ® 67 Eszopiclone 67 MIVI III 67 visilizumab 67 Eluting Stent 67 compound PMX # 67 complement inhibitor eculizumab 67 Patients Suffering 67 Pemetrexed 67 cell lymphoma CTCL 67 5 Fluorouracil 67 Antithrombin 67 armodafinil Tablets C 67 Phase 1b 67 Aptivus ® 67 Myelodysplastic Syndromes 67 R# #mg BID 67 LENALIDOMIDE 67 gets USFDA nod 67 MOVIPREP R 67 mitoxantrone plus 67 Malaria Vaccine 67 evaluating Prochymal 67 REVIVE Diabetes 67 FDA Approves 67 N acetylgalactosamine 6 67 IAP inhibitor 67 investigational oral inhibitor 67 Small Molecule 67 Advanced Pancreatic Cancer 67 Coadministration 67 PEGylated interferon beta 1a 67 Chronic Myeloid Leukemia 67 metastatic castration resistant 67 Acute Exacerbations 67 novel topoisomerase 67 Fabry Disease 67 Significantly Improved 67 Orthop Surg 67 Nilotinib 67 Cholinesterase Inhibitors 67 First Patient Treated 67 Vaccine Adjuvants 67 PDX pralatrexate 67 Dapagliflozin 67 lucinactant 67 catheter occlusion 67 EURIDIS 67 Advanced Prostate Cancer 67 Aeolus Pharmaceuticals Announces 67 Treatment Naive 67 chronic eosinophilic leukemia 67 therefore therapeutically equivalent 67 brand ciclesonide HFA 67 Nasdaq HALO 67 SAR# [004] 67 Cimzia ® certolizumab pegol 67 Elotuzumab 67 Orphan Status 67 Phase 1b clinical 67 Hepatocellular Carcinoma 67 Positive Opinion 67 mg q#h 67 reslizumab 67 Launches Generic Version 67 sorafenib Nexavar 67 Elderly Patients 67 HCl capsules 67 oral Janus kinase 67 Prophylactic Treatment 67 Glucagon Like Peptide 67 ara C 67 Phase IIa Trial 67 BiTE R 67 Phospholipase A2 67 Percutaneous Tibial Nerve Stimulation 67 EGFR HER2 67 Regeneron Pharma 67 CB2 selective receptor agonist 67 Hedgehog Pathway Inhibitor 67 HGS ETR1 mapatumumab 67 Enzastaurin 67 Phase III placebo controlled 67 Phase 1a 67 aripiprazole Abilify 67 TBC# 67 Interferon Gamma 67 ergot derivatives 67 Lymphocytic 67 Solid Tumors 67 huN# DM1 67 phase IIIb 67 Platelet Inhibition 67 prokinetic agent 67 PEGINTRON TM 67 iobenguane 67 Inc. Nasdaq OXGN 67 Chronic Lymphocytic Leukemia CLL 67 targeted radiotherapeutic 67 Bremelanotide 67 estrogen receptor beta agonist 67 Paclitaxel Carboplatin 67 6 sulfatase 67 Inflammatory Markers 67 generation DACH Platinum 67 DEB# 67 demonstrated antitumor activity 67 relapsed refractory multiple myeloma 67 Diabetic Macular Edema 67 highly selective inhibitor 67 APF# Phase 67 Acetate Rectal Suppositories 67 Bepreve TM 67 Amrubicin 67 TMC# [002] 67 PI3K/Akt pathway inhibitor 67 Gastric Cancer 67 peptidic compound 67 Sustained Efficacy 67 GATTEX ™ 67 insulin glulisine 67 5 HT2A inverse 67 Japanese Encephalitis Vaccine 66 Ixabepilone 66 bone marrow reticulin deposition 66 Protease Inhibitors 66 CRMD# 66 VIVITROL ® 66 Biomarker Study 66 Pharmaceuticals Initiates